BioTuesdays

Category - Feature

Feature

Thera sees ibalizumab as company game changer

By Len Zehr If approved by the FDA in the next few months, ibalizumab for patients with multidrug resistant HIV has the potential to be a game changer for Theratechnologies (TSX:TH). The FDA accepted ibalizumab for...

October 17, 2017
Feature

Diffusion Pharma readies pivotal hypoxic GBM trial

By Len Zehr Diffusion Pharmaceuticals (NASDAQ:DFFN) expects to begin before the end of 2017 a pivotal clinical trial with its trans sodium crocetinate (TSC) lead compound to re-oxygenate oxygen-deprived tissue in...

October 3, 2017
Feature

In conversation with Hrishikesh Suresh of NeuroGate

By Len Zehr As CEO and one of three co-founders of upstart NeuroGate, Hrishikesh Suresh currently is completing his final year as a medical student at McMaster University in Hamilton, Ontario and plans to pursue a six...

September 26, 2017
Feature

In conversation with Lloyd Segal of Repare

By Len Zehr As president and CEO of upstart Repare Therapeutics, Lloyd Segal was instrumental is arranging the initial funding to create Repare while he served as an entrepreneur-in-residence at Versant Ventures, a...

August 22, 2017